[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610658":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":36,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"250 patients with a diagnosis of uterine fibroids who underwent uterine artery embolization",null,"Women diagnosed with symptomatic uterine fibroids who underwent image-guided uterine artery embolization as treatment. No additional surgical or medical interventions were performed during the procedure.",[13],{"name":14,"affiliation":15,"role":16},"Giuseppe Cittadini, MD","IRCCS Ospedale Policlinico San Martino","STUDY_CHAIR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Emanuele Barabino, MD","CONTACT","00393331002778","emanuele.barabino@hsanmartino.it",[24],{"facility":25,"status":10,"city":26,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"IRCCS OSpedale Policlinico San Martino","Genova","16100","Italy","IT",{"type":31,"coordinates":32},"Point",[33,34],11.87211,45.21604,{"lat":34,"lon":33},{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Emanuele Barabino","Emanuele Barabino, MD, EBIR - Principal Investigator","100610658","artificial-intelligence-for-the-intra-procedural-assessment-of-uterine-artery-embolization-100610658",false,"NCT07230444","Artificial Intelligence for the Intra-procedural Assessment of Uterine Artery Embolization","Validation and Implementation With Artificial Intelligence of Software for the Intra-procedural Assessment of Uterine Artery EMBOlization","AI-EMBO","Inclusion Criteria:\n\n* Female patients ≥18 years\n* Symptomatic uterine fibroids (e.g., bleeding, bulk symptoms, pain)\n* Underwent UAE as definitive therapy\n* Availability of baseline clinical\u002Fimaging data (for retrospective arm) or ability to provide informed consent (for prospective arm)\n\nExclusion Criteria:\n\n* Lack of clinical follow-up\n* Poor quality or incomplete angiographic images.","FEMALE","18 Years","55 Years",{"count":52,"type":53},250,"ESTIMATED","6 Months","OBSERVATIONAL","Uterine artery embolization is a minimally invasive treatment for symptomatic uterine fibroids, but intra-procedural assessment of embolization adequacy currently relies on subjective angiographic criteria. This study evaluates a proprietary angiographic analysis software (AQ-VERO) that extracts quantitative time-to-density perfusion metrics in real time. The study aims to (1) validate the accuracy and reproducibility of AQ-VERO during uterine artery mebolization, and (2) develop an AI-based decision support system using AQ-VERO-derived metrics to improve objective intra-procedural assessment of treatment endpoints.",[58],"Uterine Fibroids (UF)",[60,61,62,63,64],"uterine fibroids","embolization","uterine artery embolization","quantitative imaging","artificial intelligence","NOT_YET_RECRUITING","2025-11-15",{"date":68,"type":69},"2025-11-19","ACTUAL",{"date":71,"type":53},"2025-12-01",{"date":73,"type":53},"2027-05-31",{"name":38,"class":6},1]